Company / EPS (Diluted)
Eledon Pharmaceuticals, Inc. EPS (Diluted) History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.60
FY2016
5-year range
-$38.02 / -$3.60
FY2014-FY2016
Trend
+90.5%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-31.09 to $-3.60 over the past 2 years.
Based on SEC 10-K filings.
-3.60 in FY2016.
Improved from $-31.09 to $-3.60 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, eps (diluted) increased 90.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2016 | -$3.60 | +90.5% |
| FY2015 | -$38.02 | -22.3% |
| FY2014 | -$31.09 | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026